NASDAQ Global Market • Healthcare • Biotechnology • US • USD
Curis, Inc. (CRIS) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 16 recommend buying, 2 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
